Log In Sign up
The largest database of trusted experimental protocols

Anti mouse ctla 4

Manufactured by BioXCell
Visit Supplier
Sourced in Lebanon

Anti-mouse CTLA-4 is a laboratory reagent used for research purposes. It is a monoclonal antibody that specifically binds to the CTLA-4 protein expressed on the surface of mouse cells. CTLA-4 is an important regulator of T-cell activation and immune responses.

Automatically generated - may contain errors

Lab products found in correlation

Anti mouse pd 1, by BioXCell (4 mentions) αcd38 pe cy7, by BioLegend (1 mentions) αcd8 fitc, by BioLegend (1 mentions) Dnase, by Roche (1 mentions) Liberase, by Roche (1 mentions) Sb431542, by Merck Group (1 mentions) Armenian hamster igg, by BioXCell (1 mentions) Anti mouse cd8α, by BioXCell (1 mentions) Smartstrainer, by Miltenyi Biotec (1 mentions) Tumor dissociation kit, by Miltenyi Biotec (1 mentions) Plasmocin, by InvivoGen (1 mentions) Rat igg2a, by BioXCell (1 mentions) Polyclonal syrian hamster igg, by BioXCell (1 mentions) Pacific blue ifnγ, by BioLegend (1 mentions) Af700cd45, by BioLegend (1 mentions) Cd62l pe cy7, by BioLegend (1 mentions) Percp cy5.5 pd 1, by BioLegend (1 mentions) Fixation permeabilization kit, by BD (1 mentions) Cd44 apc cy7, by BioLegend (1 mentions) Cd8a apc, by BioLegend (1 mentions)

Close spelling variants of this product

Anti‐mouse CTLA‐4 (9D9, Anti-mouse CTLA-4 (clone 9H10 or UC10–4F10–11; Anti (α)-mouse CTLA-4 Anti-mouse CTLA-4 antibody Anti-mouse CTLA-4 clone 9H10 CTLA-4,

5 protocols using anti mouse ctla 4

1

Mouse MerTK-specific ASO for Immune Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols
A mouse MerTK-specific ASO and control ASOs were produced by Ionis Pharmaceuticals, Inc. Anti-mouse CTLA-4 (Catalog# BP0164) and anti-mouse PD-1 (Catalog# BE0146) were purchased from BioXCell. Liberase (Catalog #05401127001) and DNAse (Catalog #4716728001) were purchased from Roche and Sigma-Aldrich, respectively. Flow cytometry antibodies, including αCD45-PerCP Cy5.5 (Catalog# 103131), αCD4-PE/Dazzle594 (Catalog# 100456), αCD8-FITC (Catalog# 100706), αGranzyme B (GrB)-Pacific Blue (Catalog# 515408), αGr1-BV510 (Catalog# 108437), αCD11b-APC Fire750 (Catalog# 101262), αF4/80-Alexa Fluor 700 (Catalog# 123130), αCD38-PE-Cy7 (Catalog# 102718), αCD206-PE (Catalog# 141706), and αMertK-APC (Catalog# 151507) were ordered from BioLegend.
Hu Y., Revenko A., Barsoumian H., Bertolet G., Fowlkes N.W., Maazi H., Green M.M., He K., Sezen D., Voss T.A., Leyton C.S., Masrorpour F., Rafiq Z., Puebla-Osorio N., Leuschner C., MacLeod R., Cortez M.A, & Welsh J.W. (2024). Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. Journal of Experimental & Clinical Cancer Research : CR, 43, 70.
+ Open protocol
+ Expand
2

Immunomodulatory Therapy for Melanoma

Check if the same lab product or an alternative is used in the 5 most similar protocols
The dorsal skin of C57Bl6 mice was shaved and B16F10 cells (105) implanted in the right lateral dorsal skin on day 0. In aPD1 monotherapy experiments, animals were treated on days 5, 7, and 9 with either saline i.t., 150 μg aPD1 mAb as monotherapy or 150 μg each of aPD1+aCTLA4 combination therapy mAb i.t., or 150 μg aPD1 or 150 μg each of aPD1+aCTLA4 as aPD1- or combination ICB-ANCs (respectively) i.t.. In this and all other ANC experiments, mAb delivery was dose-matched between free and ANC-conjugated treatment groups. In SB-431542 treatment experiments, after 5 (when all tumors were visible), 7, 9, 11, and 13 days, mice were injected i.d. with 30 μl containing either control treatment (vehicle); a mixture of unloaded, targeted ANCs [6 µg each of anti-mouse CTLA4- (clone:UC10–4F10–11, BioXCell) and rat anti-mouse PD1-ANCs (clone: 29F.1A12, BioXCell)] and SB431542-loaded isotype ANCs [Armenian hamster IgG- (BioXCell) and rat isotype control-ANCs (clone: 2A3, BioXCell)]; or SB431542-loaded targeted ANCs [6 µg of CTLA4-ANCs and PD1-ANCs]. 5 µg of SB-431542 (Sigma) was encapsulated in drug-loaded ANCs immediately prior to injection. Mice were monitored every other day for survival studies. For immunofluorescence studies, mice were euthanized at endpoint and tumors were harvested.
Francis D.M., Manspeaker M.P., Archer P.A., Sestito L.F., Heiler A.J., Schudel A, & Thomas S.N. (2021). Drug-Eluting Immune Checkpoint Blockade Antibody-Nanoparticle Conjugate Enhances Locoregional and Systemic Combination Cancer Immunotherapy through T Lymphocyte Targeting. Biomaterials, 279, 121184.
+ Open protocol
+ Expand
3

Tumor Immunotherapy Combination Protocol

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
All DsiRNAs were synthesized by Integrated DNA Technologies (IDT, Coralville, IA). Primer and probe oligonucleotides used in real-time qPCR detection were synthesized by IDT or Life Technologies (Carlsbad, CA). Monoclonal antibodies (anti-mouse PD-1, anti-mouse CTLA-4, and anti-mouse CD8α) were purchased from Bio X Cell (Lebanon, NH). Tumor dissociation kit and Smart Strainers used to make single-cell suspension were purchased from Miltenyi Biotec (Bergisch Gladbach, Germany). Monoclonal antibodies used for flow cytometry were purchased from BioLegend (San Diego, CA). DCR-BCAT and Placebo LNPs were prepared as previously described.19 (link) Anti PD-1 antibody, anti-CTLA-4 antibodies, and anti-CD8a antibodies were diluted in PBS and administered intraperitoneally. DCR-BCAT and DCR-Placebo (LNP with chemistry-matched, scrambled CTNNB1 DsiRNA) were given intravenously. LGK-974 was purchased from Selleckchem.com (Houston, TX). LGK-974 was dissolved in DMSO (2%) and Corn Oil (solvents added individually and in order) and was administered orally.
Ganesh S., Shui X., Craig K.P., Park J., Wang W., Brown B.D, & Abrams M.T. (2018). RNAi-Mediated β-Catenin Inhibition Promotes T Cell Infiltration and Antitumor Activity in Combination with Immune Checkpoint Blockade. Molecular Therapy, 26(11), 2567-2579.
+ Open protocol
+ Expand
4

Tumor Growth Inhibition by Immune Checkpoint Blockade

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
The tumor cell lines tested negative for mycoplasma infection and Plasmocin (InvivoGen) was used as a routine addition to the culture media to prevent mycoplasma contamination. The mice were inoculated with 1–1.5 × 105 B16F10-OVA cells or 2 × 106 MC38-OVA cells s.c. into the right flank. The mice were i.p. injected at the indicated time points with either 200 μg anti-PD-1 (29F1. A12, InVivoPlus anti-mouse PD-1, Bioxcell), anti-CTLA-4 (9H10, InVivoPlus anti-mouse CTLA-4, Bioxcell) or the respective isotype controls (anti-CTLA-4 isotype control, InVivoPlus polyclonal Syrian hamster IgG, Bioxcell; anti-PD-1 isotype control, InVivoPlus rat IgG2a isotype control, anti-trinitrophenol, Bioxcell). Tumor size was monitored every other day and tumors were harvested at the indicated time points for the analysis of tumor-infiltrating lymphocytes. Tumor volume was calculated as ½ × D × d2, where D is the major axis and d is the minor axis, as described previously45 (link). Tumor growth was monitored at least three times a week to ensure that the tumors did not exceed 25 mm in diameter.
Eschweiler S., Clarke J., Ramírez-Suástegui C., Panwar B., Madrigal A., Chee S.J., Karydis I., Woo E., Alzetani A., Elsheikh S., Hanley C.J., Thomas G.J., Friedmann P.S., Sanchez-Elsner T., Ay F., Ottensmeier C.H, & Vijayanand P. (2021). Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy. Nature immunology, 22(8), 1052-1063.
+ Open protocol
+ Expand
5

Peptide Library Synthesis and Liposome Formulation

Cited 1 time
Check if the same lab product or an alternative is used in the 5 most similar protocols
Trp2, AH1 and WT1 peptide libraries and peptides were synthesized by GenScript. CoPoP was synthesized as previously reported (32 (link)). The following lipids were used to produce liposomes: dioleoylphosphatidylcholine (DOPC; Corden #LP-R4–070), cholesterol (PhytoChol; Wilshire), and synthetic PHAD-3D6A (Avanti; #699855). QS-21 was purchased from Desert King (part number NC0949192). The APC-CD8a (Clone: CT-CD8a) antibody was obtained from Accurate Chemical and Scientific Corporation (#ACL168APC). The following antibodies were obtained from BioLegend: APC-CD8a (Clone: CT-CD8a; #100712), FITC-CD4 (Clone: GK1.5; #100405), AF700-CD45 (Clone: 30-F11; #103127), APC-Cy7-CD44 (Clone: IM7; #103027), PE/Cy7-CD62L (Clone: MEL-14; #104417), PerCP-Cy5.5-PD-1 (Clone: RMP1–30; #109119), pacific blue-IFN-γ (Clone: XMG1.2; #505818), BV605-TNF-α (Clone: MP6-XT22; #506329), PE/Cy7-Granzyme B (Clone: QA16A02; #372213). Anti-mouse PD-1 (#BP0146) and anti-mouse CTLA-4 (#BP0131) were acquired from Bio X Cell. Other reagents used were Golgiplug/Brefeldin A (BD; #555029), Live/Dead dye (Invitrogen; #L34857), Fc-block (Clone: 2.4G2; BD #553142), fixation/permeabilization kit (BD #554714), red blood cell (RBC) lysis buffer (BioVision #5830), Collagenase Type I (Gibco #17018–029), and DNase I (Roche #04536282001).
He X., Zhou S., Quinn B., Jahagirdar D., Ortega J., Long M.D., Abrams S.I, & Lovell J.F. (2022). An In Vivo Screen to Identify Short Peptide Mimotopes with Enhanced Antitumor Immunogenicity. Cancer immunology research, 10(3), 314-326.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!